Administering BOTOX^® for your overactive bladder (OAB) patients

BOTOX^® provides approximately 6 months of symptom relief⁶

Please follow the SmPC for reconstitution protocol (section 6.6). For the patient preparation and post-injection monitoring, please see section 4.4 of the SmPC

BOTOX^® in overactive bladder: Treatment benefit sustained over time⁶

BOTOX^® sustained reductions in daily episodes of UI and urgency from baseline, throughout the entire 3.5 year study period⁶

Adapted from Nitti VW, et al. 2016.⁶

Study context: The final results of the prospective, multicentre, long-term (3.5 year) study of the efficacy/safety of BOTOX^® for overactive bladder syndrome. The co-primary endpoints were the mean reduction in UI episodes per day and the proportion of patients reporting a positive response on the treatment benefit scale. In the overall population the most common AEs within the first 12 weeks of BOTOX^® treatment were localised to the urinary tract. There was no evidence of increasing occurence of these AEs with repeat treatments, UTI was the most frequently reported AE⁶

^†n values denote the number of patients with data available at week 12 post treatment. Error bars represent 95% confidence intervals.

Overall median duration of effect was 7.6 months⁶

Duration of botulinum toxin type A effect based on time to patient request for re-treatment⁶

Adapted from Nitti VW, et al. 2016.⁶

Study context: The final results of the prospective, multicenter, long-term (3.5 year) study of the efficacy/safety of BOTOX^® for overactive bladder syndrome. Median duration in patients (n=438) who received 100U BOTOX^® only throughout study with complete treatment cycles, with 1 month defined as 4 weeks. Total study duration 3.5 years. Patients received up to 6 treatment cycles.⁶

AE: adverse event; BL: baseline; SmPC: summary of product characteristics; UI: urinary incontinence; UTI: urinary tract infection.